TY - JOUR
T1 - Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site
T2 - A retrospective study of 161 cases
AU - Fayette, J.
AU - Martin, E.
AU - Piperno-Neumann, S.
AU - Le Cesne, A.
AU - Robert, C.
AU - Bonvalot, S.
AU - Ranchère, D.
AU - Pouillart, P.
AU - Coindre, J. M.
AU - Blay, J. Y.
PY - 2007/1/1
Y1 - 2007/1/1
N2 - Background: Angiosarcomas are rare, heterogeneous and a retrospective study was conducted to describe their natural history. Patients and methods: We reviewed 161 files of angiosarcoma treated in three institutions of the French Sarcoma Group from 1980 to 2004. Survival and prognostic factors for survival were analyzed. Results: Median age was 52 years. Primary sites were the breast (35%), skin (20%) and soft tissues (13%). At initial diagnosis, 31 (19%) had metastases. Surgery was the first treatment in 121 (75%) patients combined with chemotherapy or radiotherapy in 34 and 32, respectively. Ninety (74%) of these 121 patients relapsed, mostly locally (50). With an average time since initial diagnosis of 8.1 years, 123 (76%) patients progressed and 76 (47%) died. Median survival was 3.4 years [95% confidence interval (CI) 2.4-5.8], and the 5-year overall survival (OS) rate was 43% (95% CI 33-53). In multivariate analysis, liver primary site [relative risk (RR) = 12.62], performance status (PS) of two or more (RR = 3.83), presence of metastases at diagnosis (RR = 2.50), soft tissue tumor (RR = 0.31) were correlated to OS. PS, liver and soft tissue tumors were identified as independent prognostic factors for progression-free survival. Conclusions: Angiosarcomas have an overall poor outcome, but with a clearly distinct prognosis depending on the primary site.
AB - Background: Angiosarcomas are rare, heterogeneous and a retrospective study was conducted to describe their natural history. Patients and methods: We reviewed 161 files of angiosarcoma treated in three institutions of the French Sarcoma Group from 1980 to 2004. Survival and prognostic factors for survival were analyzed. Results: Median age was 52 years. Primary sites were the breast (35%), skin (20%) and soft tissues (13%). At initial diagnosis, 31 (19%) had metastases. Surgery was the first treatment in 121 (75%) patients combined with chemotherapy or radiotherapy in 34 and 32, respectively. Ninety (74%) of these 121 patients relapsed, mostly locally (50). With an average time since initial diagnosis of 8.1 years, 123 (76%) patients progressed and 76 (47%) died. Median survival was 3.4 years [95% confidence interval (CI) 2.4-5.8], and the 5-year overall survival (OS) rate was 43% (95% CI 33-53). In multivariate analysis, liver primary site [relative risk (RR) = 12.62], performance status (PS) of two or more (RR = 3.83), presence of metastases at diagnosis (RR = 2.50), soft tissue tumor (RR = 0.31) were correlated to OS. PS, liver and soft tissue tumors were identified as independent prognostic factors for progression-free survival. Conclusions: Angiosarcomas have an overall poor outcome, but with a clearly distinct prognosis depending on the primary site.
KW - Angiosarcoma
KW - Retrospective study
KW - Sarcoma
UR - http://www.scopus.com/inward/record.url?scp=37349120536&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdm381
DO - 10.1093/annonc/mdm381
M3 - Article
C2 - 17974557
AN - SCOPUS:37349120536
SN - 0923-7534
VL - 18
SP - 2030
EP - 2036
JO - Annals of Oncology
JF - Annals of Oncology
IS - 12
ER -